ATXS Stock Analysis: Buy, Sell, or Hold?
ATXS - Astria Therapeutics, Inc. Common Stock
$12.58
0.08 (0.64%)
▲
BUY
HIGH Confidence
Last Updated: January 22, 2026
Earnings: Mar 05, 2026
Get Alerted When ATXS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: ATXS shows strong fundamentals and good volume confirmation. Solid entry point despite slightly low pricing.
✅ BUY SIGNAL: ATXS shows strong fundamentals and good volume confirmation. Solid entry point despite slightly low pricing.
In-depth Analysis How we analyze
Valuation Analysis: ATXS is currently trading at $12.58, which is considered slightly low relative to its 30-day fair value range of $12.58 to $13.03.
Technical Outlook: Technically, ATXS is in a strong uptrend. The price is currently testing key support at $12.24. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $24.60 (+95.5%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, ATXS is in a strong uptrend. The price is currently testing key support at $12.24. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $24.60 (+95.5%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Fair Price Range
$12.58 -
$13.03
Company Quality Score
58/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
86.2%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Options cheap (IV 0th percentile)
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 95.5% below Wall St target ($24.60)
Fair Price Analysis
30-Day Fair Range
$12.58 -
$13.03
Current vs Fair Value
SLIGHTLY LOW
Expected Move (7 Days)
±$0.83
(6.6%)
Support & Resistance Levels
Support Level
$12.24
Resistance Level
$13.27
Current Trend
Strong Uptrend
Fundamental Context
Forward P/E (Next Year Est.)
-5.34
Wall Street Target
$24.60
(+95.5%)
Last updated: February 01, 2026 6:04 AM ET
Data refreshes hourly during market hours. Next update: 7:04 AM
Data refreshes hourly during market hours. Next update: 7:04 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ATXS showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$404 | 63 BUY |
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$64 | 55 HOLD |
|
RCKT
Rocket Pharmaceuticals I… |
STRONG BUY
18 analysts |
$8 | 53 HOLD |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$102 | 62 BUY |
|
CRNX
Crinetics Pharmaceutical… |
STRONG BUY
17 analysts |
$85 | 55 HOLD |
Advanced ATXS Option Strategies
Professional options setups generated by AI based on today's ATXS price and gamma walls.
